Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: Jul, 2016 | Pages:
78 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Toll Like Receptor 3 (CD283 or TLR3) - Pipeline Review, H2 2016 Summary Global Markets Direct's, 'Toll Like Receptor 3 (CD283 or TLR3) - Pipeline Review, H2 2016', provides in depth analysis on Toll Like Receptor 3 (CD283 or TLR3) targeted pipeline therapeutics. The report provides comprehensive information on the Toll Like Receptor 3 (CD283 or TLR3), targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Toll Like Receptor 3 (CD283 or TLR3) targeted therapeutics development and features dormant and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data. Scope - The report provides a snapshot of the global therapeutic landscape for Toll Like Receptor 3 (CD283 or TLR3) - The report reviews Toll Like Receptor 3 (CD283 or TLR3) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources - The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages - The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in Toll Like Receptor 3 (CD283 or TLR3) targeted therapeutics and enlists all their major and minor projects - The report assesses Toll Like Receptor 3 (CD283 or TLR3) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type - The report summarizes all the dormant and discontinued pipeline projects - The report reviews latest news and deals related to Toll Like Receptor 3 (CD283 or TLR3) targeted therapeutics Reasons To Buy - Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Identify and understand the targeted therapy areas and indications for Toll Like Receptor 3 (CD283 or TLR3) - Identify the use of drugs for target identification and drug repurposing - Identify potential new clients or partners in the target demographic - Develop strategic initiatives by understanding the focus areas of leading companies - Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics - Devise corrective measures for pipeline projects by understanding Toll Like Receptor 3 (CD283 or TLR3) development landscape - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Table of Contents
Table of Contents 2 List of Tables 5 List of Figures 5 Introduction 6 Global Markets Direct Report Coverage 6 Toll Like Receptor 3 (CD283 or TLR3) Overview 7 Therapeutics Development 8 Toll Like Receptor 3 (CD283 or TLR3) - Products under Development by Stage of Development 8 Toll Like Receptor 3 (CD283 or TLR3) - Products under Development by Therapy Area 9 Toll Like Receptor 3 (CD283 or TLR3) - Products under Development by Indication 10 Toll Like Receptor 3 (CD283 or TLR3) - Pipeline Products Glance 12 Late Stage Products 12 Early Stage Products 13 Toll Like Receptor 3 (CD283 or TLR3) - Products under Development by Companies 14 Toll Like Receptor 3 (CD283 or TLR3) - Products under Development by Universities/Institutes 17 Toll Like Receptor 3 (CD283 or TLR3) - Therapeutics Assessment 19 Assessment by Monotherapy/Combination Products 19 Assessment by Mechanism of Action 20 Assessment by Route of Administration 22 Assessment by Molecule Type 24 Toll Like Receptor 3 (CD283 or TLR3) - Companies Involved in Therapeutics Development 26 Biomics Biotechnologies Co., Ltd. 26 Hemispherx Biopharma, Inc. 27 Idera Pharmaceuticals, Inc. 28 Innate Pharma S.A. 29 Johnson & Johnson 30 MultiCell Technologies, Inc. 31 Oncovir, Inc. 32 Tollys S.A.S 33 Toll Like Receptor 3 (CD283 or TLR3) - Drug Profiles 34 Antibody to Antagonize TLR3 for Acute and Chronic Inflammatory Diseases - Drug Profile 34 Product Description 34 Mechanism Of Action 34 R&D Progress 34 Antisense RNAi Oligonucleotide to Agonize TLR-3 for Age Related Macular Degeneration - Drug Profile 35 Product Description 35 Mechanism Of Action 35 R&D Progress 35 CNTO-3157 - Drug Profile 36 Product Description 36 Mechanism Of Action 36 R&D Progress 36 Drugs to Activate TLR3 for Atherosclerosis - Drug Profile 37 Product Description 37 Mechanism Of Action 37 R&D Progress 37 IPH-33 - Drug Profile 38 Product Description 38 Mechanism Of Action 38 R&D Progress 38 MCT-465 - Drug Profile 39 Product Description 39 Mechanism Of Action 39 R&D Progress 39 Oligonucleotide to Agonize TLR3 for Oncology - Drug Profile 41 Product Description 41 Mechanism Of Action 41 R&D Progress 41 Oligonucleotides to Agonize TLR3 for Infectious Disease and Immunology - Drug Profile 42 Product Description 42 Mechanism Of Action 42 R&D Progress 42 P-7 - Drug Profile 43 Product Description 43 Mechanism Of Action 43 R&D Progress 43 Poly-ICLC - Drug Profile 44 Product Description 44 Mechanism Of Action 44 R&D Progress 44 rabies vaccine - Drug Profile 47 Product Description 47 Mechanism Of Action 47 R&D Progress 47 rintatolimod - Drug Profile 48 Product Description 48 Mechanism Of Action 48 R&D Progress 48 Small Molecule to Antagonize TLR-3 for Gastrointestinal Syndrome - Drug Profile 57 Product Description 57 Mechanism Of Action 57 R&D Progress 57 Small Molecules to Antagonize TLR-3 for Infectious Disease and Immunology - Drug Profile 58 Product Description 58 Mechanism Of Action 58 R&D Progress 58 Stathmin-1 - Drug Profile 59 Product Description 59 Mechanism Of Action 59 R&D Progress 59 Toll Like Receptor 3 (CD283 or TLR3) - Dormant Projects 60 Toll Like Receptor 3 (CD283 or TLR3) - Discontinued Products 63 Toll Like Receptor 3 (CD283 or TLR3) - Featured News & Press Releases 64 Jun 07, 2016: Hemispherx Biopharma: Dr. William M. Mitchell Publishes Article Titled, "Efficacy of Rintatolimod in the Treatment of Chronic Fatigue Syndrome/Myalgic Encephalomyelitis (CFS/ME)" in Expert Review of Clinical Pharmacology 64 Jun 06, 2016: Hemispherx Biopharma Obtains a Comprehensive Carter Omnibus Assignment of Intellectual Property 65 Mar 10, 2016: Hemispherx Biopharma Reviews Ampligen Data with National Institute of Neurological Disorders and Stroke 65 Feb 09, 2016: Hemispherx Biopharma Exploring Possible Research Program in Zika Virus Using Ampligen 66 Jan 04, 2016: Yisheng Biopharma Announces Positive Results of Phase I Clinical Trial of a Novel Rabies Vaccine with PIKA Adjuvant 66 Sep 28, 2015: Hemispherx Biopharma Receives the European Patent Office Grant of New Composition of Matter Patent Covering Ampligen Formulations 68 Sep 23, 2015: Hemispherx Biopharma Reports Article by Senior Authors from Italian Ministry of Health and Related Agencies Suggesting Broad Applicability of Ampligen to Multiple Sclerosis 69 Sep 21, 2015: Hemispherx Biopharma Research Team Identifies Characteristics of Chronic Fatigue Syndrome Patients Potentially Predictive of Improved Response to Ampligen 70 Sep 17, 2015: Hemispherx Biopharma Announces Patient Assistance Program for Chronic Fatigue Syndrome Open Label Study 71 Sep 15, 2015: Hemispherx Biopharma Reports Low NK Cell Activity in Chronic Fatigue Syndrome and Relationship to Disease Symptoms 72 Aug 10, 2015: Hemispherx Enters into an Agreement with myTomorrows for an Early Access Program for Rintatolimod in Europe 72 Jun 25, 2015: Hemispherx Receives the European Patent Office Examining Division's Notice of Intention to Grant the New Composition of Matter Patent Covering Ampligen Formulations 73 May 26, 2015: Hemispherx Biopharma Europe : Orphan Medicine Designation and European Medicines Agency Public Opinion Summary Published by EMA Regarding Ampligen/Rintatolimod for Ebola Virus Disease 74 May 11, 2015: Hemispherx Biopharma Europe Receives Orphan Medicine Designation by the European Medicines Agency for Ampligen to Treat Patients With Ebola Virus Disease (EVD) 74 Mar 24, 2015: Hemispherx Biopharma Europe Receives Positive Opinion on Application for Orphan Designation by the European Medicines Agency for Ampligen to Treat Patients With Ebola Virus Disease (EVD) 75 Appendix 77 Methodology 77 Coverage 77 Secondary Research 77 Primary Research 77 Expert Panel Validation 77 Contact Us 77 Disclaimer 78
List of Tables
Number of Products under Development for, H2 2016 8 Number of Products under Development by Therapy Area, H2 2016 9 Number of Products under Development by Indication, H2 2016 10 Comparative Analysis by Late Stage Development, H2 2016 12 Comparative Analysis by Early Stage Products, H2 2016 13 Number of Products under Development by Companies, H2 2016 14 Products under Development by Companies, H2 2016 15 Products under Development by Companies, H2 2016 (Contd..1) 16 Number of Products under Investigation by Universities/Institutes, H2 2016 17 Products under Investigation by Universities/Institutes, H2 2016 18 Assessment by Monotherapy/Combination Products, H2 2016 19 Number of Products by Stage and Mechanism of Action, H2 2016 21 Number of Products by Stage and Route of Administration, H2 2016 23 Number of Products by Stage and Molecule Type, H2 2016 25 Pipeline by Biomics Biotechnologies Co., Ltd., H2 2016 26 Pipeline by Hemispherx Biopharma, Inc., H2 2016 27 Pipeline by Idera Pharmaceuticals, Inc., H2 2016 28 Pipeline by Innate Pharma S.A., H2 2016 29 Pipeline by Johnson & Johnson, H2 2016 30 Pipeline by MultiCell Technologies, Inc., H2 2016 31 Pipeline by Oncovir, Inc., H2 2016 32 Pipeline by Tollys S.A.S, H2 2016 33 Dormant Projects, H2 2016 60 Dormant Projects (Contd..1), H2 2016 61 Dormant Projects (Contd..2), H2 2016 62 Discontinued Products, H2 2016 63
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
